Details of the Drug

General Information of Drug (ID: DM5I621)

Drug Name

Methyldopa

Synonyms

AMD; Aldometil; Aldomin; Alphamethyldopa; Baypresol; Becanta; Dopamet; Dopamethyperpax; Dopatec; Dopegit; Dopegyt; Dopergit; Grospisk; Hyperpax; Hypolag; Medomet; Medopa; Medopal; Medopren; Methoplain; Methyldopum; Metildopa; Novomedopa; Presinol; Presolisin; Sedometil; Sembrina; Alpha medopa; Methyl dopa; Methyldopa anhydrous; Aldoril D30; Aldoril D50; Bayer 1440 L; LT00847269; MK 351; Aldomet (TN); Aldoril (TN); Alpha-Methyl dopa; Alpha-Methyldihydroxyphenylalanine; Alpha-Methyldopa; Apo-Methyldopa; Dopamet (TN); Dopegyt (TN); L-Methyl Dopa; L-Methyldopa; METHYL DOPA (SEE ALSO METHYL DOPA SESQUIHYDRATE); MK-351; Methyldopa (INN); Methyldopa (anhydrous); Methyldopum [INN-Latin]; Metildopa [INN-Spanish]; Mk. b51; Nr.C 2294; Nu-Medopa; Alpha-Methyldopa (VAN); L-alpha-Methyl DOPA; L-alpha-Methyldopa; Methyl-L-dopa; Aldoril, Dopamet, Dopegyt, Methyldopa; L-(alpha-Md); Methyldopa (L,-); Alpha-Methyl-L-3,4-dihydroxyphenylalanine; L-alpha-Methyl-3,4-dihydroxyphenylalanine; L-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine; Alpha-Methyl-beta-(3,4-dihydroxyphenyl)-L-alanine; L(-)-beta-(3,4-Dihydroxyphenyl)-alpha-methylalanine; L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic acid; L-(-)-3-(3,4-Dihydroxyphenyl)-2-methylalanine; L-(-)-alpha-Methyl-beta-(3,4-dihydroxyphenyl)alanine; (-)-3-(3,4-Dihydroxyphenyl)-2-Methyl-L-Alanine Sesqui-Hydrate; (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; (S)-(-)-alpha-Methyldopa; 3-(3,4-DIHYDROXYPHENYL)-2-METHYL-L-ALANINE; 3-Hydroxy-.alpha.-methyl-L-tyrosine; 3-Hydroxy-alpha-methyl-L-tyrosine

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

211.21

Logarithm of the Partition Coefficient (xlogp)

-1.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 888 mcg/L [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability: The bioavailability of drug is 38% [2]
Clearance: The renal clearance of drug is 130 mL/min [4]
Elimination: Approximately 70% of absorbed methyldopa is excreted in the urine as unchanged parent drug (24%) and -methyldopa mono-O-sulfate (64%), with variability.3-O-methyl--methyldopa accounted for about 4% of urinary excretion products [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 105 minutes [4]
Metabolism: The drug is metabolized via the liver [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 157.65596 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.85% [8]
Vd: The volume of distribution (Vd) of drug is 0.19-0.32 L/kg [9]
Water Solubility: The ability of drug to dissolve in water is measured as 10 mg/mL [3]

Chemical Identifiers

Formula: C10H13NO4
IUPAC Name: (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid
Canonical SMILES: C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N
InChI: InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1
InChIKey: CJCSPKMFHVPWAR-JTQLQIEISA-N

Cross-matching ID

PubChem CID: 38853
ChEBI ID: CHEBI:61058
CAS Number: 555-30-6
DrugBank ID: DB00968
TTD ID: D0BA6T
VARIDT ID: DR00596
INTEDE ID: DR1051
ACDINA ID: D00417

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[11]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[11]
Sulfotransferase 1A1 (SULT1A1)	DEYWLRK	ST1A1_HUMAN	Substrate	[12]
Thiopurine methyltransferase (TPMT)	DEFQ8VO	TPMT_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Catechol O-methyltransferase (COMT)	OTPWKTQG	COMT_HUMAN	Biotransformations	[14]
Glutathione S-transferase A1 (GSTA1)	OTA7K5XA	GSTA1_HUMAN	Gene/Protein Processing	[15]
Glutathione S-transferase Mu 1 (GSTM1)	OTSBF2MO	GSTM1_HUMAN	Gene/Protein Processing	[15]
Glutathione S-transferase P (GSTP1)	OTLP0A0Y	GSTP1_HUMAN	Gene/Protein Processing	[15]
Prolactin (PRL)	OTWFQGX7	PRL_HUMAN	Gene/Protein Processing	[16]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Hypertension

ICD Disease Classification

BA00-BA04

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Sulfotransferase 1A1 (SULT1A1)	DME	SULT1A1	8.47E-01	3.57E-02	1.73E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	7.36E-01	1.62E-02	1.08E-01
Thiopurine methyltransferase (TPMT)	DME	TPMT	1.32E-01	-6.42E-02	-2.31E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Methyldopa (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Methyldopa and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[17]
Methylene blue	DMJAPE7	Major	Decreased metabolism of Methyldopa caused by Methylene blue mediated inhibition of non-CYP450 enzyme.	Acquired methaemoglobinaemia [3A93]	[18]
Glibenclamide	DM8JXPZ	Minor	Decreased metabolism of Methyldopa caused by Glibenclamide.	Acute diabete complication [5A2Y]	[19]
Glipizide	DMZA5PQ	Minor	Decreased metabolism of Methyldopa caused by Glipizide.	Acute diabete complication [5A2Y]	[19]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Methyldopa and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[20]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Methyldopa and Cariprazine.	Bipolar disorder [6A60]	[21]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Methyldopa and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[22]
Selegiline	DM6034S	Major	Decreased metabolism of Methyldopa caused by Selegiline mediated inhibition of non-CYP450 enzyme.	Depression [6A70-6A7Z]	[18]
Isocarboxazid	DMAF1NB	Major	Decreased metabolism of Methyldopa caused by Isocarboxazid mediated inhibition of non-CYP450 enzyme.	Depression [6A70-6A7Z]	[18]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Methyldopa and OPC-34712.	Depression [6A70-6A7Z]	[21]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Methyldopa and Cannabidiol.	Epileptic encephalopathy [8A62]	[23]
Procarbazine	DMIK367	Major	Decreased metabolism of Methyldopa caused by Procarbazine mediated inhibition of non-CYP450 enzyme.	Hodgkin lymphoma [2B30]	[18]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Methyldopa and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[24]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Methyldopa and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[25]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Methyldopa and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[26]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Methyldopa and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[27]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Methyldopa and ITI-007.	Insomnia [7A00-7A0Z]	[21]
Iron	DMAP8MV	Moderate	Decreased absorption of Methyldopa due to formation of complexes caused by Iron.	Iron deficiency anaemia [3A00]	[28]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Methyldopa and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[29]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Methyldopa and Idelalisib.	Mature B-cell leukaemia [2A82]	[30]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Methyldopa and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[31]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Methyldopa and Lasmiditan.	Migraine [8A80]	[32]
Ozanimod	DMT6AM2	Major	Decreased metabolism of Methyldopa caused by Ozanimod mediated inhibition of non-CYP450 enzyme.	Multiple sclerosis [8A40]	[33]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Methyldopa and Promethazine.	Nausea/vomiting [MD90]	[21]
Safinamide	DM0YWJC	Major	Decreased metabolism of Methyldopa caused by Safinamide mediated inhibition of non-CYP450 enzyme.	Parkinsonism [8A00]	[18]
Opicapone	DM1BKA6	Moderate	Decreased metabolism of Methyldopa caused by Opicapone mediated inhibition of non-CYP450 enzyme.	Parkinsonism [8A00]	[34]
Rasagiline	DM3WKQ4	Major	Decreased metabolism of Methyldopa caused by Rasagiline mediated inhibition of non-CYP450 enzyme.	Parkinsonism [8A00]	[18]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Methyldopa and Levomepromazine.	Psychotic disorder [6A20-6A25]	[21]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Methyldopa and Leflunomide.	Rheumatoid arthritis [FA20]	[26]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Methyldopa and Quetiapine.	Schizophrenia [6A20]	[21]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Methyldopa and Aripiprazole.	Schizophrenia [6A20]	[21]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Methyldopa and Iloperidone.	Schizophrenia [6A20]	[21]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Methyldopa and Paliperidone.	Schizophrenia [6A20]	[21]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Methyldopa and Molindone.	Schizophrenia [6A20]	[21]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Methyldopa and Thiothixene.	Schizophrenia [6A20]	[21]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Methyldopa and Amisulpride.	Schizophrenia [6A20]	[21]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Methyldopa and Asenapine.	Schizophrenia [6A20]	[21]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Methyldopa and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[23]
Tolbutamide	DM02AWV	Minor	Decreased metabolism of Methyldopa caused by Tolbutamide.	Type 2 diabetes mellitus [5A11]	[19]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Methyldopa and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[35]
-----------


⏷ Show the Full List of 40 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Calcium sulfate anhydrous	E00303	24497	Desiccant; Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Edetate disodium	E00186	8759	Complexing agent
Magnesium stearate	E00208	11177	lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Methyldopa 500 mg tablet	500 mg	Oral Tablet	Oral
Methyldopa 250 mg tablet	250 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5217).
2	Jiao SS, Yao XQ, Liu YH, Wang QH, Zeng F, Lu JJ, Liu J, Zhu C, Shen LL, Liu CH, Wang YR, Zeng GH, Parikh A, Chen J, Liang CR, Xiang Y, Bu XL, Deng J, Li J, Xu J, Zeng YQ, Xu X, Xu HW, Zhong JH, Zhou HD, Zhou XF, Wang YJ: Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits. Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5225-30. doi: 10.1073/pnas.1422998112. Epub 2015 Apr 6.
3	BDDCS applied to over 900 drugs
4	DailyMed Label: METHYLDOPA oral tablet, film coated
5	BUHS RP, BECK JL, SPETH OC, SMITH JL, TRENNER NR, CANNON PJ, LARAGH JH: THE METABOLISM OF METHYLDOPA IN HYPERTENSIVE HUMAN SUBJECTS. J Pharmacol Exp Ther. 1964 Feb;143:205-14.
6	Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB: PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics. 2013 Oct;23(10):563-85. doi: 10.1097/FPC.0b013e328364db84.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9	Gupta M, Al Khalili Y: Methyldopa .
10	Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405.
11	Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. J Clin Pharmacol. 2002 Mar;42(3):342-6.
12	Platelet phenol sulfotransferase and erythrocyte catechol-O-methyltransferase activities: correlation with methyldopa metabolism. Clin Pharmacol Ther. 1984 Jan;35(1):55-63.
13	Identification, characterization, and ontogenic study of a catechol O-methyltransferase from zebrafish. Aquat Toxicol. 2011 Mar;102(1-2):18-23.
14	Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol Pharmacol. 2001 Feb;59(2):393-402. doi: 10.1124/mol.59.2.393.
15	Inhibition of human glutathione S-transferases by dopamine, alpha-methyldopa and their 5-S-glutathionyl conjugates. Chem Biol Interact. 1994 Jan;90(1):87-99.
16	Neonatal effects of methyldopa therapy in pregnancy hypertension. Acta Paediatr Hung. 1991;31(1):53-65.
17	Cerner Multum, Inc. "Australian Product Information.".
18	Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
19	Gachalyi B, Tornyossy, Vas A, Kaldor A "Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man." Int J Clin Pharmacol Ther Toxicol 18 (1980): 133-5. [PMID: 6103880]
20	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
21	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
22	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
23	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
24	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
25	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
26	Canadian Pharmacists Association.
27	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
28	Campbell N, Paddock V, Sundaram R "Alteration of methyldopa absorption, metabolism, and blood pressure control caused by ferrous sulfate and ferrous gluconate." Clin Pharmacol Ther 43 (1988): 381-6. [PMID: 3356082]
29	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
30	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
31	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
32	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
33	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
34	Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A "The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine." Clin Pharmacol Ther 58 (1995): 221-7. [PMID: 7648772]
35	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.